Preliminary Results from Zimmer Biomet mymobility Study

Preliminary results from a prospective, randomized controlled clinical trial of Zimmer Biomet’s mymobility® with Apple Watch® remote care management platform indicate that the platform for primary knee replacement demonstrated similar early outcomes to traditional care while requiring significantly few physical therapy visits.

mymobility enables frequent, virtual connections between patients and healthcare professionals to facilitate remote episode of care management and lower the overall cost of care. mymobility patients reported fewer emergency department visits and lower rates of hospital readmission.

The 90-day study evaluated 448 total or partial knee patients, randomized to a mymobility smartphone-based exercise and educational group vs. control (traditional care). Data showed no significant differences between the mymobility and control groups in range of motion of the treated knee or manual manipulation of the knee under anesthesia. Further, the mymobility group required significantly fewer physical therapy visits.

Zimmer Biomet’s mymobility on Apple Watch and iPhone leverages sensors to monitor a patient’s real-time activity and post-op progress. Information is delivered to the patient’s care team so they can make data-driven decisions regarding recovery and risk of complications.

“We’re very excited to debut early results from one of the largest clinical studies in orthopedics designed to evaluate the impact of the mymobility remote care management platform on patient outcomes and overall costs of care,” said Yvonne Bokelman, Vice President, Clinical Affairs and Market Access, at Zimmer Biomet. “An integral part of our end-to-end connected-care solutions, mymobility uses data informatics and digital technology to facilitate communications and engagement between patients and healthcare professionals. It is designed to improve adherence to recovery regimens and increase efficiency and value across the entire continuum of care.”